Autologous cytokine-induced killer cells in the treatment of multiple myeloma concomitant with lung cancer and paraneoplastic dermatoses

Intern Med. 2010;49(21):2341-6. doi: 10.2169/internalmedicine.49.3996. Epub 2010 Nov 1.


Cytokine-induced killer (CIK) cells have been shown to be effective in the treatment of advanced cancer and minimal residual diseases. We report a multiple myeloma (MM) patient with concomitant lung cancer and paraneoplastic dermatoses, who received cellular immunotherapy with CIK cells which were derived from peripheral blood mononuclear cells (PBMCs) after being primed with anti-cluster of differentiation 3 (CD3) monoclonal antibody, interleukin-2 (IL-2), interferon-γ (IFN-γ) and IL-1. After treatment MM and lung cancer remained stable and no progression or recurrence was observed. Paraneoplastic dermatoses were obviously improved after treatment, which was first reported. No evident side effects were observed. These findings suggested that cellular immunotherapy with CIK cells was safe and effective in this patient with MM and lung cancer, and it might be a potent therapeutic option for paraneoplastic dermatoses.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Cells, Cultured
  • Cytokine-Induced Killer Cells / transplantation*
  • Hand Dermatoses / complications
  • Hand Dermatoses / pathology
  • Hand Dermatoses / therapy*
  • Humans
  • Immunotherapy, Adoptive* / methods
  • Lung Neoplasms / complications
  • Lung Neoplasms / pathology
  • Lung Neoplasms / therapy*
  • Male
  • Multiple Myeloma / complications
  • Multiple Myeloma / pathology
  • Multiple Myeloma / therapy*
  • Paraneoplastic Syndromes / complications
  • Paraneoplastic Syndromes / pathology
  • Paraneoplastic Syndromes / therapy*
  • Transplantation, Autologous